GSK’s Zejula Wins First-Line Ovarian Cancer Use

The US Food and Drug Administration has approved GlaxoSmithKline PLC’s Zejula (niraparib) as a first line maintenance treatment of women with ovarian cancer, bringing the PARP inhibitor – which GSK acquired last year by buying Tesaro for $5.1bn – its third indication for the disease. Axel Hoos, GSK’s head of oncology R&D, told Scrip the oral, once-daily therapy would soon enter studies in lung and breast cancer.

The FDA approval for Zejula as a first-line treatment in ovarian cancer was announced 29 April and is based on data from the PRIMA study, a double-blind, randomized Phase III...